

6th MDR Eudamed Clinical Investigation Performance Study WG meeting

Implementation plan update

19/09/2019 DG GROW

Content

- 1. Meetings
- 2. Project deliverables
- 3. Features Priorities / Status of Templates
- 4. State of play FS level
- 5. Implementation plan update



Meetings

- 19/09/2019 Clinical Investigations WG
- 03/10/2019 Data Exchange
- 24/10/2019 NB & Certificates WG



Project deliverables

- Eudamed information system
 - Restricted site
 - Public site
- Data Exchange solutions
- User guide
- Technical documentation (for Data Exchange)
- Training material
- Application Support
- Playground



Feature priority

Features	EUDAMED Priority
Serious Adverse Events	3rd Release (5/2021)
Application / notification Management	4th Release (5/2022)
End Report	4th Release (5/2022)
Coordinated Assessment Procedure	4th Release (5/2022)



State of play 1/7

FS-CIPS-001: Manage application/notification for CI/PS

Analysis and requirements to be finalised by June 2020

FS-CIPS-002: Withdraw application or notification for CI/PS or PMCF/PMPF

Analysis and requirements to be finalised by November 2020

FS-CIPS-003: Manage validation of application for CI/PS and setting of validation date

Analysis and requirements to be finalised by June 2020



State of play 2/7

FS-CIPS-004: Manage authorisation of CI/PS and setting of time limit for authorisation

Analysis and requirements finalised by June 2020

FS-CIPS-015: Manage list of Ethics Committees

Analysis requirements to be finalised by January 2021

FS-CIPS-005: Enter and communicate the start of the CI/PS or re-start after a suspension or temporary halt or start with substantial modification

Analysis requirements to be finalised by January 2021

FS-CIPS-006: Manage substantial modifications to CI/PS after authorisation or PMCF/PMPF

Analysis requirements to be finalised by January 2021



State of play 3/7

FS-CIPS-007: Manage authorisation for substantial modifications to CI/PS or PMCF/PMPF

Analysis and requirements finalised by January 2021

FS-CIPS-008: Manage recording and reporting of adverse events that occur during CI/PS

Analysis and requirements finalised by June 2020

FS-CIPS-009: Manage information at the end of a CI/PS or PMCF/PMPF or in the event of a temporary halt or early termination

Analysis and requirements finalised by January 2021



State of play 4/7

FS-CIPS-010: Manage coordinated assessment procedure for CI/PS

Analysis and requirements finalised by January 2021

FS-CIPS-011: Manage exchange of information and communication to all MS and the Commission on decisions and the grounds therefore related to CI/PS

 Analysis and requirements finalised by January 2021 (depending on FS-CIPS-003, FS-CIPS-004, FS-CIPS-007)

FS-CIPS-012: Search and view information on CIPS (only for SAE)

- SAE Analysis and requirements finalised by June 2020
- Remaining Analysis and requirements finalised by January 2021



State of play 5/7

FS-CIPS-013: Machine to machine (M2M) CI/PS information *upload*

- SAE Analysis and requirements finalised by June 2020
- Remaining Analysis and requirements finalised by January 2021

FS-CIPS-014: Machine to machine (M2M) CI/PS information *download*

- SAE Analysis and requirements finalised by June 2020
- Remaining Analysis and requirements finalised by January 2021



State of play 6/7

FS for public site - specifications will follow after the specifications for the restricted site (to follow in parallel)

- FS-PUB-CIPS-001: Search and view CI/PS
 (application/notification) information and related updates for related information made publicly available
- FS-PUB-CIPS-002: Search and view CI/PS reports and summaries made publicly available
- FS-PUB-CIPS-003: Search and view reported adverse events and device deficiencies and related updates for related information made publicly available (tbd)
- FS-PUB-CIPS-004 : Protect subjects data




Playground

 The Eudamed First Playground on CIPS (with SAE) will be available around Q1 2021 (for Third Release).




Implementation Plan 1/2





Implementation Plan 2/2





Q & A

Thank-you for your collaboration!

